Drugs / NeoVax
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03361852 | Mar 2022 → Dec 2026 expected | follicular lymphoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04930783 | Jan 2022 → Dec 2027 expected | melanoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03219450 | Aug 2021 → Jul 2027 expected | lymphoid leukemia | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04024878 | Nov 2020 → Apr 2025 overdue | ovarian cancer | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03929029 | Nov 2020 → Dec 2022 overdue | cutaneous melanoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03422094 | Oct 2018 → Apr 2020 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03422094 ↗ |
| Known as | Personalized Neoantigen Vaccine | “This research study is a Pilot Study, which is the first time investigators are examining the Personalized Neoantigen Vaccine (NeoVax) in patients diagnosed with follicular lymphoma.” NCT03361852 ↗ |
| Modality | Vaccine | “This is the first time NeoVax vaccine will be given in combination with cyclophosphamide and Pembrolizumab in humans.” NCT03219450 ↗ |
| Route | Subcutaneous | “by subcutaneous injection.” NCT03422094 ↗ |